Valuation: Charles River Laboratories International, Inc.

Market Cap 14.06B 12.37B 11.7B 10.61B 19.92B 1,350B 20.04B 140B 54.09B 689B 52.8B 51.66B 2,214B P/E 2026 *
78.3x
P/E 2027 * 31.5x
Enterprise Value 16.18B 14.23B 13.45B 12.2B 22.92B 1,553B 23.05B 161B 62.21B 792B 60.73B 59.41B 2,546B EV / Sales 2026 *
4.13x
EV / Sales 2027 * 3.92x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Charles River Laboratories International, Inc.

1 day+0.92%
1 week+6.87%
Current month+5.11%
1 month+2.77%
3 months+42.82%
1 week 235.96
Extreme 235.956
243.6
1 month 221.61
Extreme 221.613
243.6
Current year 146.62
Extreme 146.619
243.6
1 year 146.62
Extreme 146.619
243.6
3 years 146.62
Extreme 146.619
243.6
5 years 146.62
Extreme 146.619
243.6
10 years 146.62
Extreme 146.619
243.6
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer - 2021-01-31
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+6.87% - - 14.06B
-0.12%+3.70%+12.27%+37.12% 49.06B
+0.22%+0.40%+50.91%+37.06% 44.6B
-1.58%+4.66%+359.34%+614.38% 43.24B
+1.70%+0.36%+12.56%+99.27% 41.73B
+0.51%-1.71%+5.18%+46.87% 29.93B
-0.48%-1.32%+23.98%+150.01% 17.19B
+0.08%+9.03%+8.41% - 15.35B
-2.01%-2.30%+26.88%+44.19% 15.54B
+1.97%-3.17% - - 15.11B
Average +0.11%+1.85%+62.44%+146.98% 30.19B
Weighted average by Cap. +0.10%+2.26%+78.12%+161.01%

Financials

2026 *2027 *
Net sales 3.92B 3.45B 3.26B 2.96B 5.55B 376B 5.58B 39.02B 15.07B 192B 14.71B 14.39B 617B 4.01B 3.52B 3.33B 3.02B 5.68B 385B 5.71B 39.89B 15.41B 196B 15.04B 14.71B 631B
Net income 164M 144M 136M 124M 233M 15.75B 234M 1.63B 631M 8.04B 616M 603M 25.83B 431M 379M 359M 325M 611M 41.39B 614M 4.29B 1.66B 21.12B 1.62B 1.58B 67.86B
Net Debt 2.11B 1.86B 1.76B 1.59B 2.99B 203B 3.01B 21.03B 8.12B 103B 7.93B 7.76B 332B 1.63B 1.44B 1.36B 1.23B 2.31B 157B 2.33B 16.26B 6.28B 80B 6.13B 6B 257B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
26-09-28 CHF 243.60 +0.92%
26-09-25 CHF 241.39 +0.54%
26-09-24 CHF 240.10 +1.75%
26-09-23 CHF 235.96 +0.15%
26-09-22 CHF 235.59 +3.36%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
294.59USD
Average target price
301.29USD
Spread / Average Target
+2.27%

Quarterly revenue - Rate of surprise